Feature | September 11, 2012

Maquet Study Results May Invalidate Industry Standard for Treating Cardiogenic Shock

The Impella percutaneous left ventricular assist devices (pLVAD) is an emerging option for partial or total circulatory support. In several randomized, controlled trials, pLVAD therapy demonstrated a better hemodynamic profile compared to IABP, although this did not translate into improved 30-day survival with use of pLVAD therapy.

September 11, 2012 — Primary results from an ongoing trial by Maquet Cardiovascular using intra-aortic balloon pumps (IABP) as an adjuvant treatment for myocardial infarction (MI) complicated by cardiogenic shock have shown no difference in patient survival when compared to standard care alone. Although IABP proved to be safe, the study’s results provide little evidence that use of IABP therapy is associated with hemodynamic improvement, a trait that has been considered critical to its clinical application for more than 40 years. The IABP-SHOCK II trial, conducted between 37 centers in Germany with 600 randomized patients over the course of three years, represents the largest trial ever performed in cardiogenic shock.


Since their introduction in 1968, IABPs have been the most widely used support device in the treatment of MI complicated by cardiogenic shock, with several million people having received treatment using IABP therapy to date. IABP provides temporary, mechanical circulatory support in an attempt to create a more favorable balance of oxygen supply and demand. Through systolic unloading and diastolic augmentation, the cardiac output, ejection fraction (EF) and rate of coronary perfusion are increased, while left ventricular wall stress, systemic resistance to left EF, and pulmonary capillary wedge pressure are decreased. Use of IABP therapy for cardiogenic shock patients during the ‘80s and ‘90s was limited to around 20 percent of cases; however, there has been a temporal trend towards increased use over the years, with rates currently estimated at 25 to 40 percent.


Until now, only a few registry studies and clinical trials have shown that IABP therapy can improve blood pressure and the perfusion of the coronary arteries. Based on this limited data, international guidelines recommend the use of IABP therapy in patients with cardiogenic shock, although, as evident in the frequency of use, many cardiologists are still not entirely convinced of its efficacy. It was for this reason that the IABP-SHOCK II trial was initiated, aiming to provide evidence that use of IABP therapy, currently a Class I recommendation, would reduce the 30-day mortality rate in patients compared to standard care. Besides failing to reduce rates of mortality, use of IABP showed no improvement in blood pressure, no reduction in treatment time in the intensive care unit, no decrease in the duration or dose of drugs prescribed and no improvement in organ perfusion. Several subgroups were additionally evaluated and also showed no clear benefit in using IABP.


While IABP therapy is currently the workhorse circulatory support device used by cardiovascular specialists, GlobalData believes that the Class I recommendation will now be strongly challenged. Previous studies have explored the use of IABP and even reported positive results; however, no trials have had the breadth, statistical significance and randomization of the SHOCK II trial. With this most recent announcement of SHOCK II’s primary results, it is expected that cardiologists will further question continued use of IABP therapy, although six-month and 12-month mortality data must be assessed before any definitive conclusions can be made.


Treatment strategies for patients with cardiogenic shock have come to a key turning point, and results of this most recent IABP trial have left a therapeutic void to fill. Percutaneous left ventricular assist devices (pLVAD) represent an emerging option for partial or total circulatory support and more than one study has compared the safety and efficacy of these devices with IABP. In several randomized, controlled trials, pLVAD therapy demonstrated a better hemodynamic profile compared to IABP, although this did not translate into improved 30-day survival with use of pLVAD therapy. The most common pLVADs studied currently are the TandemHeart developed by CardiacAssist and the Abiomed Impella LP2.5. As pLVAD technology continues to improve, further studies will be required to determine its effectiveness. Muscular counterpulsation exemplifies a noninvasive alternative to IABP therapy and has shown some promise, although more clinical research must be conducted before conclusions can be made.


Besides Maquet, who recently acquired Datascope’s cardiovascular portfolio, other companies with IABP products include Arrow and Abiomed. The results of the SHOCK II study provide a huge opportunity to develop novel and innovative strategies to treat cardiogenic shock, and room for another company to seize market control for this indication. GlobalData expects IABP therapy will be targeted to a more specific target population in future studies where it is deemed most effective, and that pLVAD therapy may undergo further development to improve survival rates.


For more information: www.globaldata.com/ExpertsInsightDetails.aspx?PRID=347&companyID=jpr


Related Content

Navidea, Mass General, Tc99m-tilmanocept, vulnerable plaque, cardiovascular disease, Harvard
News | Radiopharmaceuticals and Tracers| July 30, 2015
Navidea Biopharmaceuticals Inc. announced plans to move forward with a joint study of the ability of Tc99m-tilmanocept...
MSCs, stem cells, end-stageheart failure, retrograde, coronary sinus,
News | Stem Cell Therapies| July 29, 2015
A new clinical trial to test how a high dose of stem cells delivered via a method called retrograde coronary sinus...
heart failure, Adaptive CRT trial, AdaptivCRT algorithm, readmissions
News | Heart Failure| July 22, 2015
Heart failure patients had a significantly lower chance of being readmitted within 30 days of discharge when treated...
Direct Flow Medical, Transcatheter Aortic Valve System, SALUS Trial, FDA
News | Heart Valve Repair| July 22, 2015
Direct Flow Medical Inc. received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug...
HeartMate PHP, Thoratec, St. Jude medical

The HeartMate PHP (percutaneous heart pump) is the latest acute hemodynamic support technology released by Thoratec, which recently received CE mark in Europe. The PHP is currently in U.S.clinical trials.

Feature | Ventricular Assist Devices (VAD)| July 22, 2015
St. Jude Medical and Thoratec announced that the boards of directors of both companies have unanimously approved a...
Xarelto, anticoagulant protocol, discharge, outcomes, DVT, PE
News | Antiplatelet and Anticoagulation Therapies| July 21, 2015
Two companion papers published in Academic Emergency Medicine  address the question of when it is appropriate to...
UNC, biomarkers, severe heart disease, fructosamine, LDL cholesterol, Nichols
News | Cardiac Diagnostics| July 21, 2015
Insulin resistance affects tens of millions of Americans and is a big risk factor for heart disease. Yet, some people...
Feature | Atrial Fibrillation| July 20, 2015
A new study proves race and gender-related disparities exist in care for patients who have recently been diagnosed with...
Boston Scientific, fully absorbable scaffold, FAST study, resorbable
Feature | Stents Bioresorbable| July 20, 2015
Boston Scientific has initiated a study of the company's first fully resorbable drug-eluting scaffold system. The Fully...
Veryan Medical, BioMimics 3D femoropopliteal stent, MIMICS-2 study, PAD
News | Stents Peripheral| July 17, 2015
Veryan Medical announced that the first subject has been enrolled in their MIMICS-2 study at Universitäts-Herzzentrum...
Overlay Init